Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells

详细信息    查看全文

• 作者：Seth M Pollack (1) (2)
  Robin L Jones (1) (2)
  Erik A Farrar (1)
  Ivy P Lai (1) (8)
  Sylvia M Lee (1) (2)
  Jianhong Cao (1)
  Venu G Pillarisetty (1) (3)
  Benjamin L Hoch (4)
  Ashley Gullett (4)
  Marie Bleakley (1) (5)
  Ernest U Conrad III (6)
  Janet F Eary (7)
  Kendall C Shibuya (1)
  Edus H Warren (1) (2)
  Jason N Carstens (1)
  Shelly Heimfeld (1)
  Stanley R Riddell (1) (2) (8)
  Cassian Yee (1) (2) (9)
  
  1. Clinical Research Division ; D3-100 Fred Hutchinson Cancer Research Center ; 1100 Fairview Ave ; Seattle ; WA ; 98109 ; USA
  2. Department of Medicine ; University of Washington ; Seattle ; WA ; USA
  8. Institute for Advanced Study ; Technical University of Munich ; Munich ; Germany
  3. Department of Surgery ; University of Washington ; Seattle ; WA ; USA
  4. Department of Pathology ; University of Washington ; Seattle ; WA ; USA
  5. Department of Pediatrics ; University of Washington ; Seattle ; WA ; USA
  6. Department of Orthopedics ; University of Washington ; Seattle ; WA ; USA
  7. Department of Radiology ; University of Alabama ; Birmingham ; AL ; USA
  9. Department of Melanoma Medical Oncology ; UT MD Anderson Cancer Center ; 7455 Fannin St ; Unit 904 ; Houston ; TX ; 77054 ; USA
  
• 关键词：Adoptive T cell therapy ; NY ; ESO ; 1 ; Synovial sarcoma ; Myxoid ; Liposarcoma ; Immunotherapy ; Antigen specific T cells ; Tetramer ; Influx cell sorting
• 刊名：Journal for Immunotherapy of Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：2
• 期：1
• 全文大小：910 KB
• 参考文献：1. Restifo, NP, Dudley, ME, Rosenberg, SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: pp. 269-281 CrossRef
  2. Chapuis, AG, Thompson, JA, Margolin, KA, Rodmyre, R, Lai, IP, Dowdy, K, Farrar, EA, Bhatia, S, Sabath, DE, Cao, J, Li, Y, Yee, C (2012) Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 109: pp. 4592-4597 CrossRef
  3. Hunder, NN, Wallen, H, Cao, J, Hendricks, DW, Reilly, JZ, Rodmyre, R, Jungbluth, A, Gnjatic, S, Thompson, JA, Yee, C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: pp. 2698-2703 CrossRef
  4. Park, JR, Digiusto, DL, Slovak, M, Wright, C, Naranjo, A, Wagner, J, Meechoovet, HB, Bautista, C, Chang, WC, Ostberg, JR, Jensen, MC (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15: pp. 825-833
  5. Robbins, PF, Morgan, RA, Feldman, SA, Yang, JC, Sherry, RM, Dudley, ME, Wunderlich, JR, Nahvi, AV, Helman, LJ, Mackall, CL, Kammula, US, Hughes, MS, Restifo, NP, Raffeld, M, Lee, CC, Levy, CL, Li, YF, El-Gamil, M, Schwarz, SL, Laurencot, C, Rosenberg, SA (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: pp. 917-924 CrossRef
  6. Porter, DL, Levine, BL, Kalos, M, Bagg, A, June, CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: pp. 725-733 CrossRef
  7. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG, Bartido, S, Stefanski, J, Taylor, C, Olszewska, M, Borquez-Ojeda, O, Qu, J, Wasielewska, T, He, Q, Bernal, Y, Rijo, IV, Hedvat, C, Kobos, R, Curran, K, Steinherz, P, Jurcic, J, Rosenblat, T, Maslak, P, Frattini, M, Sadelain, M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: pp. 177ra138 CrossRef
  8. Morgan, RA, Chinnasamy, N, Abate-Daga, D, Gros, A, Robbins, PF, Zheng, Z, Dudley, ME, Feldman, SA, Yang, JC, Sherry, RM, Phan, GQ, Hughes, MS, Kammula, US, Miller, AD, Hessman, CJ, Stewart, AA, Restifo, NP, Quezado, MM, Alimchandani, M, Rosenberg, AZ, Nath, A, Wang, T, Bielekova, B, Wuest, SC, Akula, N, McMahon, FJ, Wilde, S, Mosetter, B, Schendel, DJ, Laurencot, CM (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: pp. 133-151 CrossRef
  9. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM, Royal, RE, Topalian, SL, Kammula, US, Restifo, NP, Zheng, Z, Nahvi, A, Vries, CR, Rogers-Freezer, LJ, Mavroukakis, SA, Rosenberg, SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: pp. 126-129 CrossRef
  10. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A, June, CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: pp. 95ra73 CrossRef
  11. Bendle, GM, Linnemann, C, Hooijkaas, AI, Bies, L, Witte, MA, Jorritsma, A, Kaiser, AD, Pouw, N, Debets, R, Kieback, E, Uckert, W, Song, JY, Haanen, JB, Schumacher, TN (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16: pp. 565-570 CrossRef
  12. Coccoris, M, Straetemans, T, Govers, C, Lamers, C, Sleijfer, S, Debets, R (2010) T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther 10: pp. 547-562 CrossRef
  13. Yee, C, Thompson, JA, Byrd, D, Riddell, SR, Roche, P, Celis, E, Greenberg, PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: pp. 16168-16173 CrossRef
  14. Butler, MO, Friedlander, P, Milstein, MI, Mooney, MM, Metzler, G, Murray, AP, Tanaka, M, Berezovskaya, A, Imataki, O, Drury, L, Brennan, L, Flavin, M, Neuberg, D, Stevenson, K, Lawrence, D, Hodi, FS, Velazquez, EF, Jaklitsch, MT, Russell, SE, Mihm, M, Nadler, LM, Hirano, N (2011) Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3: pp. 80ra34 CrossRef
  15. Dannull, J, Su, Z, Rizzieri, D, Yang, BK, Coleman, D, Yancey, D, Zhang, A, Dahm, P, Chao, N, Gilboa, E, Vieweg, J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: pp. 3623-3633 CrossRef
  16. Attia, P, Powell, DJ, Maker, AV, Kreitman, RJ, Pastan, I, Rosenberg, SA (2006) Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 29: pp. 208-214 CrossRef
  17. Rasmussen, AM, Borelli, G, Hoel, HJ, Lislerud, K, Gaudernack, G, Kvalheim, G, Aarvak, T (2010) Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods 355: pp. 52-60 CrossRef
  18. Li, Y, Yee, C (2008) IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111: pp. 229-235 CrossRef
  19. Li, Y, Bleakley, M, Yee, C (2005) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175: pp. 2261-2269 CrossRef
  20. Pollack, SM, Jungbluth, AA, Hoch, BL, Farrar, EA, Bleakley, M, Schneider, DJ, Loggers, ET, Rodler, E, Eary, JF, Conrad, EU, Jones, RL, Yee, C (2012) NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118: pp. 4564-4570 CrossRef
  21. Jungbluth, AA, Antonescu, CR, Busam, KJ, Iversen, K, Kolb, D, Coplan, K, Chen, YT, Stockert, E, Ladanyi, M, Old, LJ (2001) Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94: pp. 252-256 CrossRef
  22. Singer, S, Baldini, EH, Demetri, GD, Fletcher, JA, Corson, JM (1996) Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 14: pp. 1201-1208
  23. Pollack, SM, Li, Y, Blaisdell, MJ, Farrar, EA, Chou, J, Hoch, BL, Loggers, ET, Rodler, E, Eary, JF, Conrad, EU, Jones, RL, Yee, C (2012) NYESO-1/LAGE-1s and PRAME Are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-Deoxycitabine. PLoS One 7: pp. e32165 CrossRef
  24. Neudorfer, J, Schmidt, B, Huster, KM, Anderl, F, Schiemann, M, Holzapfel, G, Schmidt, T, Germeroth, L, Wagner, H, Peschel, C, Busch, DH, Bernhard, H (2007) Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 320: pp. 119-131 CrossRef
  25. Wang, X, Schmitt, A, Chen, B, Xu, X, Mani, J, Linnebacher, M, Freund, M, Schmitt, M (2010) Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol 38: pp. 1066-1073 CrossRef
  26. Robbins, PF, Li, YF, El-Gamil, M, Zhao, Y, Wargo, JA, Zheng, Z, Xu, H, Morgan, RA, Feldman, SA, Johnson, LA, Bennett, AD, Dunn, SM, Mahon, TM, Jakobsen, BK, Rosenberg, SA (2008) Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180: pp. 6116-6131 CrossRef
  27. Linette, GP, Stadtmauer, EA, Maus, MV, Rapoport, AP, Levine, BL, Emery, L, Litzky, L, Bagg, A, Carreno, BM, Cimino, PJ, Binder-Scholl, GK, Smethurst, DP, Gerry, AB, Pumphrey, NJ, Bennett, AD, Brewer, JE, Dukes, J, Harper, J, Tayton-Martin, HK, Jakobsen, BK, Hassan, NJ, Kalos, M, June, CH (2013) Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122: pp. 863-871 CrossRef
  28. Chapuis, AG, Ragnarsson, GB, Nguyen, HN, Chaney, CN, Pufnock, JS, Schmitt, TM, Duerkopp, N, Roberts, IM, Pogosov, GL, Ho, WY, Ochsenreither, S, W枚lfl, M, Bar, M, Radich, JP, Yee, C, Greenberg, PD (2013) Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5: pp. 174ra27 CrossRef
  29. Chapuis, AG, Afanasiev, OK, Iyer, JG, Paulson, KG, Parvathaneni, U, Hwang, JH, Lai, I, Roberts, IM, Sloan, HL, Bhatia, S, Shibuya, KC, Gooley, T, Desmarais, C, Koelle, DM, Yee, C, Nghiem, P (2014) Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2: pp. 27-36 CrossRef
  30. Wolfl, M, Kuball, J, Ho, WY, Nguyen, H, Manley, TJ, Bleakley, M, Greenberg, PD (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110: pp. 201-210 CrossRef
  31. Ayyoub, M, Pignon, P, Classe, JM, Odunsi, K, Valmori, D (2013) CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg. Cancer Immunol Res 1: pp. 303-308 CrossRef
  32. Yang, J, James, EA, Huston, L, Danke, NA, Liu, AW, Kwok, WW (2006) Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin Immunol 120: pp. 21-32 CrossRef
  33. Bender, A, Sapp, M, Schuler, G, Steinman, RM, Bhardwaj, N (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196: pp. 121-135 CrossRef
  34. Riddell, SR, Greenberg, PD (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128: pp. 189-201 CrossRef
  35. Kawai, A, Naito, N, Yoshida, A, Morimoto, Y, Ouchida, M, Shimizu, K, Beppu, Y (2004) Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 204: pp. 105-113 CrossRef
  36. Aman, P, Ron, D, Mandahl, N, Fioretos, T, Heim, S, Arheden, K, Willen, H, Rydholm, A, Mitelman, F (1992) Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 5: pp. 278-285 CrossRef
  37. Akatsuka, Y, Martin, EG, Madonik, A, Barsoukov, AA, Hansen, JA (1999) Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 53: pp. 122-134 CrossRef
  
• 刊物主题：Oncology;
• 出版者：BioMed Central
• ISSN：2051-1426

文摘

Background Adoptive T cell therapy represents an attractive modality for the treatment of patients with cancer. Peripheral blood mononuclear cells have been used as a source of antigen specific T cells but the very low frequency of T cells recognizing commonly expressed antigens such as NY-ESO-1 limit the applicability of this approach to other solid tumors. To overcome this, we tested a strategy combining IL-21 modulation during in vitro stimulation with first-in-class use of tetramer-guided cell sorting to generate NY-ESO-1 specific cytotoxic T lymphocytes (CTL). Methods CTL generation was evaluated in 6 patients with NY-ESO-1 positive sarcomas, under clinical manufacturing conditions and characterized for phenotypic and functional properties. Results Following in vitro stimulation, T cells stained with NY-ESO-1 tetramer were enriched from frequencies as low as 0.4% to >90% after single pass through a clinical grade sorter. NY-ESO-1 specific T cells were generated from all 6 patients. The final products expanded on average 1200-fold to a total of 36 billion cells, were oligoclonal and contained 67-97% CD8+, tetramer+ T cells with a memory phenotype that recognized endogenous NY-ESO-1. Conclusion This study represents the first series using tetramer-guided cell sorting to generate T cells for adoptive therapy. This approach, when used to target more broadly expressed tumor antigens such as WT-1 and additional Cancer-Testis antigens will enhance the scope and feasibility of adoptive T cell therapy.